Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person Phosphorylated heterodimers of ERBB2 KD mutants and ERBB3 bind PI3K

Class:Id	Reaction:9664646
_displayName	Phosphorylated heterodimers of ERBB2 KD mutants and ERBB3 bind PI3K
_doRelease	TRUE
_timestamp	2019-11-12 18:16:17
authored	[InstanceEdit:9656339] Orlic-Milacic, Marija, 2019-07-31
compartment	[Compartment:70101] cytosol [Compartment:876] plasma membrane
created	[InstanceEdit:9664647] Orlic-Milacic, Marija, 2019-10-25
disease	[Disease:1500689] cancer
edited	[InstanceEdit:9665760] Orlic-Milacic, Marija, 2019-11-01
entityFunctionalStatus	[EntityFunctionalStatus:9664669] gain_of_function of p-ERBB2 KD mutants:NRG1/NRG2:p-10Y-ERBB3 [plasma membrane]
input	[Complex:9664653] p-ERBB2 KD mutants:NRG1/NRG2:p-10Y-ERBB3 [plasma membrane] [Homo sapiens] [Complex:1806218] PIK3CA:PIK3R1 [cytosol] [Homo sapiens]
isChimeric	FALSE
literatureReference	[LiteratureReference:9649397] Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib [LiteratureReference:9646787] Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2) [LiteratureReference:9646445] Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer [LiteratureReference:9646758] Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification [LiteratureReference:9647026] An Acquired HER2^T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer [LiteratureReference:9652195] Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2 [LiteratureReference:9646962] Phosphorylation of mutationally introduced tyrosine in the activation loop of HER2 confers gain-of-function activity [LiteratureReference:9646964] Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor [LiteratureReference:9665642] HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors
modified	[InstanceEdit:9664660] Orlic-Milacic, Marija, 2019-10-26 [InstanceEdit:9664670] Orlic-Milacic, Marija, 2019-10-26 [InstanceEdit:9664756] Orlic-Milacic, Marija, 2019-10-28 [InstanceEdit:9665666] Orlic-Milacic, Marija, 2019-10-31 [InstanceEdit:9666039] Orlic-Milacic, Marija, 2019-11-01 [InstanceEdit:9666040] Orlic-Milacic, Marija, 2019-11-01 [InstanceEdit:9666041] Orlic-Milacic, Marija, 2019-11-01 [InstanceEdit:9666042] Orlic-Milacic, Marija, 2019-11-01 [InstanceEdit:9667512] Orlic-Milacic, Marija, 2019-11-12 [InstanceEdit:9830342] Matthews, Lisa, 2023-03-08
name	Phosphorylated heterodimers of ERBB2 KD mutants and ERBB3 bind PI3K
normalReaction	[Reaction:1250189] Binding of PI3K to ERBB2:p-ERBB3 heterodimer [Homo sapiens]
output	[Complex:9664654] p-ERBB2 KD mutants:NRG1/NRG2:p-10Y-ERBB3:PI3K [plasma membrane] [Homo sapiens]
precedingEvent	[Reaction:9664588] ERBB2 KD mutants trans-autophosphorylate [Homo sapiens] [Reaction:9664567] ERBB2 KD mutants heterodimerize [Homo sapiens]
releaseDate	2019-12-10
reviewed	[InstanceEdit:9662685] Kancha, Rama Krishna, 2019-09-16
reviewStatus	[ReviewStatus:9821382] five stars
species	[Species:48887] Homo sapiens
stableIdentifier	[StableIdentifier:9664649] R-HSA-9664646.2
summation	[Summation:9664648] Many ERBB3-binding ERBB2 KD mutants were shown to activate P...
(hasEvent)	[Pathway:9664565] Signaling by ERBB2 KD Mutants [Homo sapiens]
(precedingEvent)	[Reaction:9664664] PI3K bound to phosphorylated heterodimers of ERBB2 KD mutants and ERBB3 converts PIP2 to PIP3 [Homo sapiens]
(updatedInstance)	[_UpdateTracker:9835707] Update Tracker - [Reaction:9664646] Phosphorylated heterodimers of ERBB2 KD mutants and ERBB3 bind PI3K - v85:[modifyText]
[Change default viewing format]

No pathways have been reviewed or authored by Phosphorylated heterodimers of ERBB2 KD mutants and ERBB3 bind PI3K (9664646)